Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 889-894

  Ohno, Kousaku ^a   Tanaka, Hisako ^a   Samata, Naozumi ^a   Jakubowski, Joseph A ^b   Tomizawa, Atsuyuki ^a   Mizuno, Makoto ^a   Sugidachi, Atsuhiro ^a  

^a DAIICHI SANKYO CO   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Adenine nucleotide; P2Y12 antagonist; Platelet; Prasugrel; Sickle cell disease

Indexed keywords

ADENINE NUCLEOTIDE; BIOLOGICAL MARKER; PRASUGREL; PURINERGIC P2 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; FLOW CYTOMETRY; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; SICKLE CELL ANEMIA; THROMBOCYTE ACTIVATION; TREATMENT RESPONSE; ANEMIA, SICKLE CELL; ANIMAL; BLOOD; COMPLICATION; CYTOLOGY; DRUG EFFECTS; FEMALE; MALE; METABOLISM; THROMBOCYTE;

ANEMIA, SICKLE CELL; ANIMALS; BIOLOGICAL MARKERS; BLOOD PLATELETS; FEMALE; MALE; MICE; P-SELECTIN; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES;

EID: 84908222334     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.07.035     Document Type: Article

References (23)

1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-31.
2. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005;31:184-94.
3. Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger III AL, et al. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol 2013;75:1433-44.
4. Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger III AL, et al. A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation. Thromb Res 2014;133:190-5.
5. Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013;6:17.
6. Frelinger III AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, et al. Platelet Activation and Inhibition in Sickle cell disease (PAINS) study. Platelets 2014;25(1):27-35.
7. Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions 1984;15:199-212 [Suppl.].
8. Pászty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997;278:876-8.
9. Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 2006;116:808-16.
10. Manci EA, Hillery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS. Pathology of Berkeley sickle cellmice: similarities and differences with human sickle cell disease. Blood 2006;107:1651-8.
11. Shet AS, Hoffmann TJ, Jirouskova M, Janczak CA, Stevens JR, Adamson A, et al. Morphological and functional platelet abnormalities in Berkeley sickle cell mice. Blood Cells Mol Dis 2008;41:109-18.
12. Hashimoto M, Sugidachi A, Isobe T, Niitsu Y, Ogawa T, Jakubowski JA, et al. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel. Biochem Pharmacol 2007;74:1003-9.
13. Harkness RA, Coade SB, Webster AD. ATP, ADP and AMP in plasma from peripheral venous blood. Clin Chim Acta 1984;143:91-8.
14. Zhang Y, Dai Y, Wen J, Zhang W, Grenz A, Sun H, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med 2011;17:79-86.
15. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362(4-5):299-309.
16. Helms CC, Marvel M, Zhao W, Stahle M, Vest R, Kato GJ, et al. Mechanisms of hemolysis-associated platelet activation. J Thromb Haemost 2013;11(12):2148-54.
17. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn J, Hebbel RP, Monroe DM, et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 2014;123(11):1747-56.
18. Figueiredo RT, Fernandez PL, Mourao-Sa DS, Porto BN, Dutra FF, Alves LS, et al. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem 2007;282(28):20221-9.
19. Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash AI, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014;123(3):377-90.
20. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006;107(2):637-41.
21. Freedman ML, Karpatkin S. Elevated platelet count and megathrombocyte number in sickle cell anemia. Blood 1975;46:579-82.
22. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84(2):643-9.
23. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342(25):1855-65.